Compile Data Set for Download or QSAR
Report error Found 59 Enz. Inhib. hit(s) with all data for entry = 8553
TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258417(US9505786, 61)
Affinity DataIC50: 15nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258372(US9505786, 10)
Affinity DataIC50: 15nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258383(US9505786, 21)
Affinity DataIC50: 22nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258381(US9505786, 19)
Affinity DataIC50: 38nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258377(US9505786, 15)
Affinity DataIC50: 40nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258411(US9505786, 53)
Affinity DataIC50: 41nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258386(US9505786, 24)
Affinity DataIC50: 48nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258394(US9505786, 32)
Affinity DataIC50: 110nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258397(US9505786, 35)
Affinity DataIC50: 120nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258407(US9505786, 46)
Affinity DataIC50: 120nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258392(US9505786, 30)
Affinity DataIC50: 130nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258384(US9505786, 22)
Affinity DataIC50: 130nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258385(US9505786, 23)
Affinity DataIC50: 140nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258409(US9505786, 51)
Affinity DataIC50: 140nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258412(US9505786, 54)
Affinity DataIC50: 145nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258380(US9505786, 18)
Affinity DataIC50: 150nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258370(US9505786, 8)
Affinity DataIC50: 150nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258413(US9505786, 55)
Affinity DataIC50: 190nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258369(US9505786, 7-1)
Affinity DataIC50: 200nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258389(US9505786, 27)
Affinity DataIC50: 215nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258401(US9505786, 39)
Affinity DataIC50: 240nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258402(US9505786, 40)
Affinity DataIC50: 250nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258373(US9505786, 11)
Affinity DataIC50: 250nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258418(US9505786, 5-2)
Affinity DataIC50: 250nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258379(US9505786, 17)
Affinity DataIC50: 260nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258420(US9505786, 5)
Affinity DataIC50: 260nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258393(US9505786, 31)
Affinity DataIC50: 260nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258390(US9505786, 28)
Affinity DataIC50: 310nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258415(US9505786, 57)
Affinity DataIC50: 320nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258421(US9505786, 7)
Affinity DataIC50: 340nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258419(US9505786, 7-2)
Affinity DataIC50: 350nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258367(US9505786, 5-1)
Affinity DataIC50: 350nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258378(US9505786, 16)
Affinity DataIC50: 410nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258391(US9505786, 29)
Affinity DataIC50: 420nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258364(US9505786, 2)
Affinity DataIC50: 490nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258399(US9505786, 37)
Affinity DataIC50: 500nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258414(US9505786, 56)
Affinity DataIC50: 570nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258374(US9505786, 12)
Affinity DataIC50: 580nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258416(US9505786, 58)
Affinity DataIC50: 660nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258375(US9505786, 13)
Affinity DataIC50: 660nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258400(US9505786, 38)
Affinity DataIC50: 690nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258395(US9505786, 33)
Affinity DataIC50: 870nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258406(US9505786, 44)
Affinity DataIC50: 870nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258382(US9505786, 20)
Affinity DataIC50: 920nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258398(US9505786, 36)
Affinity DataIC50: 1.10E+3nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258368(US9505786, 6)
Affinity DataIC50: 1.10E+3nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258396(US9505786, 34)
Affinity DataIC50: 1.20E+3nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258363(US9505786, 1)
Affinity DataIC50: 1.20E+3nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258404(US9505786, 42)
Affinity DataIC50: 1.30E+3nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

TargetcGMP-specific 3',5'-cyclic phosphodiesterase(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM258366(US9505786, 4)
Affinity DataIC50: 1.30E+3nMpH: 7.5 T: 2°CAssay Description:To determine their in vitro action on human PDE 5, the test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series (1...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/13/2017
Entry Details
Go to US Patent

Displayed 1 to 50 (of 59 total ) | Next | Last >>
Jump to: